stockrow
Saturday 7 November 2026
Export MLYS’s income statement to Excel — free account
Mineralys Therapeutics, Inc.
MLYS Healthcare Biotechnology
- EPS
- −331.8%
- Free cash flow
- −7.91%
Quarter to June 2026, against a year earlier
15.35
0.11
+0.72%
Follow MLYS
Alert me
Mineralys Therapeutics, Inc. (MLYS) P/E ratio
Mineralys Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| TSHA Taysha Gene Therapies, Inc. compare | n/m |
| MLYS Mineralys Therapeutics, Inc. | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| DMRA Galecto, Inc. compare | 24.7× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)